Chronic Lymphocytic Leukemia

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for ibrutinib in combination with rituximab for use in treatment-naïve patients with chronic lymphocytic leukemia.

Othman Al-Sawaf, MD, discusses ongoing minimal residual disease assessment for patients in the phase 3 CLL14 study with chronic lymphocytic leukemia.

Matthew S. Davids, MD, MMSc, discusses the design of the UNITY trials in patients with relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.

Ian W. Flinn, MD, PhD, discusses the adverse effects associated with BTK inhibitors in B-cell malignancies, as well as the design of an ongoing phase 2 study with zanubrutinib.

Othman Al-Sawaf, MD, discusses the data from the CLL14 trial with obinutuzumab/venetoclax and the benefits of a fixed-dose treatment in select patients with chronic lymphocytic leukemia.

Paolo Ghia, MD, PhD, discusses the final results from the phase 3 ASCEND trial with acalabrutinib monotherapy in patients with relapsed/refractory CLL.

Paolo Ghia, MD, PhD, discusses how use the of chemotherapy is decreasing in favor of novel agents in chronic lymphocytic leukemia.

Paolo Ghia, MD, PhD, discusses the efficacy and safety of acalabrutinib in the phase 3 ASCEND trial in relapsed/refractory chronic lymphocytic leukemia.

Matthew S. Davids, MD, MMSc, discusses the rationale for examining ibrutinib in combination with umbralisib in relapsed/refractory chronic lymphocytic leukemia or mantle cell lymphoma.

Othman Al-Sawaf, MD, discusses benefits of a fixed duration treatment versus continuous treatment in chronic lymphocytic leukemia.

Data in Richter’s transformation, Hodgkin lymphoma, Waldenström macroglobulinemia, and indolent lymphoma were presented at the 2020 ASCO Virtual Scientific Program, and although not entirely practice changing, are deserving of attention.

Acalabrutinib continued to show favorable efficacy with a tolerable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia.

Patients with relapsed chronic lymphocytic leukemia and B-cell lymphoma who received the anti-CD19 CAR T-cell therapy FMC63-28Z experienced highly durable rates of remission, according to long-term data from a phase 1/2 study.